Trial Profile

Phase 2 Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amcenestrant (Primary) ; Letrozole
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
Focus Pharmacodynamics
Acronyms AMEERA-4
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

10 Nov 2023 Results published in the Breast Cancer Research
07 Jun 2022 Final results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
30 Sep 2021 This trial has been completed in France, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com